



ASX Release

22 August 2018

ZELDA THERAPEUTICS LIMITED
ACN 103 782 378

Level 26
140 St Georges Terrace
Perth Western Australia 6000
Tel: +61 8 6558 0886
Fax: +61 8 6316 3337
enquiries@zeldatherapeutics.com
www.zeldatherapeutics.com

Contact

Dr Richard Hopkins
Managing Director
+61 405 656 868
rhopkins@zeldatherapeutics.com

Directors

Dr Richard Hopkins
Mr Harry Karelis
Dr Stewart Washer
Ms Mara Gordon
Mr Jason Peterson

Tickers:

Australia (ASX): ZLD
USA (OTC): ZLDAF

Ordinary Shares:

755,341,934

Options:

46,000,000

1,500,000 (\$0.04 – 6/2/2020)

*4,500,000 (\$0.04 – 6/2/2020)

40,000,000 (\$0.03125 – 17/11/2021)

* subject to vesting conditions

Two Key Clinical Appointments to Medical Advisory Board

- **Professor David Casarett is a leading palliative care physician and researcher at Duke University in North Carolina with a core interest in medicinal cannabis**
- **Dr Dustin Sulak is a high-profile medicinal cannabis practitioner who has treated over 18,000 patients in the US**
- **Appointments add clinical expertise and depth to Zelda's world-class advisory board**
- **Supports development of Zelda's novel medicinal cannabis therapies for autism, insomnia and cancer**

Zelda Therapeutics Ltd (ASX: ZLD, OTCQB: ZLDAF, "Zelda" or the Company) has appointed two leading medicinal cannabis experts to its Scientific and Medical Advisory Board. Professor David Casarett and Dr Dustin Sulak are internationally recognised as key opinion leaders in the clinical use of medicinal cannabis and are both based in the United States.

Zelda Therapeutics Managing Director Dr Richard Hopkins said, "We are delighted Dr Casarett and Dr Sulak have agreed to join our Scientific and Medical Advisory Board. They bring extensive expertise in the use of medicinal cannabis that will inform our clinical programmes for indications including autism, insomnia and cancer. Their ability to access US-based patient groups will also support our strategy to bring Zelda-branded products to market."

These appointments further strengthen Zelda's world-class Scientific and Medical Advisory Board. The other members include Professor Manuel Guzmán, Full Professor of Biochemistry and Molecular Biology at Madrid's Complutense University; Dr Cristina Sánchez, an Assistant Professor at Complutense University, Madrid Spain; and, Dr Noah Federman, Director of the Pediatric Bone and Soft Tissue Sarcoma Program at University of California (Los Angeles), part of the UCLA Sarcoma Program and UCLA's Jonsson Comprehensive Cancer Center.

As members of the Medical Advisory Board, Dr Casarett and Dr Sulak, or their nominees, will be issued 1,500,000 Options pursuant to the Employee Share Option Plan (ESOP Options).

The ESOP Options will be issued in two tranches:

- **Tranche 1: 1,000,000 ESOP Options with an exercise price of \$0.125 each, vesting immediately and expire on 22 August 2021; and**
- **Tranche 2: 2,000,000 ESOP Options with an exercise price of \$0.125 each, vesting on 22 August 2020 and expire on 22 August 2021.**

Dr David Casarett MD MA

David Casarett is a leading palliative care physician and health services researcher whose work focuses on improving systems of care for people with serious life-threatening illnesses. He is a Professor of Medicine at the prestigious Duke University School of Medicine, and the Chief of Palliative Care in Duke Health. His research and clinical interests include evaluating the use of cannabis to treat neuropathic pain and nausea.

Dr Casarett is the author of more than 100 articles in journals including *JAMA* and *The New England Journal of Medicine*, and his writing has appeared in print and online in *Salon*, *Esquire*, *Discover*, *Newsweek*, *the New York Times* and *Wired*. Dr Casarett is also the author of three non-fiction books including “*Stoned: A Doctor’s Case for Medical Marijuana*”, which lays-out the case for medicinal cannabis use.

Dr Casarett is a recipient of the Presidential Early Career Award for Scientists and Engineers, the highest honour given by the US government to researchers in the early stages of their careers.

Dr Dustin Sulak

Dustin Sulak is an integrative medicine practitioner and leader in the emerging field of cannabinoid medicine. His clinical practice focuses on treating refractory conditions in adults and children. He received his undergraduate degrees in nutrition science and biology from Indiana University, a doctorate of osteopathy from the Arizona College of Osteopathic Medicine and completed an internship at Maine-Dartmouth Family Medicine Residency.

Dr Sulak is the founder of two specialist clinics in the US that have treated over 18,000 patients with medical cannabis. Dr Sulak is also the founder of Tested Labs, a cannabis analytic laboratory, and healer.com, a medical cannabis education resource. He sits on the board of directors of the Society of Cannabis Clinicians and lectures internationally on the science and clinical applications of cannabis. As an expert and educator on medical cannabis in the US, Dr Sulak has contributed to the standard of care for the use of medical cannabis in a wide variety of conditions including epilepsy, autism, pain, spasticity, seizure disorders and PTSD.

Tim Slate

Company Secretary

About Zelda Therapeutics (www.zeldatherapeutics.com)

Zelda Therapeutics Ltd (“Zelda”) is an Australian-based bio-pharmaceutical company that is focused on developing a range of cannabinoid-based formulations for the treatment of a variety of medical conditions. The Company has a two-pronged strategy comprising:

- A **human clinical trial programme** focused on insomnia, autism and eczema with activities in Australia, Chile and the USA.
- A **pre-clinical research programme** examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.

It has partnered with the world’s leading cancer cannabis researchers at Complutense University Madrid in Spain to conduct certain pre-clinical work testing cannabis-based formulations known to have an effect in humans in order to generate data packs in a form expected by regulators and the pharmaceutical industry. A similar programme is in place with the Australian Telethon Kids Institute targeting paediatric brain cancer and Curtin University targeting pancreatic cancer and cognitive decline.